Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?
Yükleniyor...
Tarih
Yazarlar
Süreli Yayın başlığı
Süreli Yayın ISSN
Cilt Başlığı
ISSN
DOI No
10.1093/annonc/mdu473
Diğer Tanımlayıcı No
Cilt
26
Sayı
1
JAN
JAN
Yayınevi
Özet
This letter criticize the design of ACTS-CC trial
patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.
patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.